EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen

Bergur V Stefánsson, Börje Haraldsson, Ulf Nilsson

Nephron Extra · 2011

DOI: 10.1159/000329889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephron Extra, 2011. Verfasst von Bergur V Stefánsson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Clinical Medicine-Nephrology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims:At our hemodialysis (HD) unit, we noted a drop in the treatment dose of erythropoietin-stimulating agents (ESAs) when the frequency of dose adjustment was reduced from weekly, where doses were withheld if hemoglobin was >130 g/l, to monthly, where doses were not withheld. The aim of this study was to find an explanation for this reduction in ESA requirement.

Methods

This is a retrospective study on 18 stable HD patients. Comparable follow-up periods of 6 months with the two different ESA adjustment regimens were established and data on ESA dose, hemoglobin and known predictors of ESA response were collected.

Results

With the new ESA administration regimen, a 22.5% drop in the total ESA dose was noted. The corresponding fall in the erythropoietin resistance index was 20.0%. Simultaneously, the dialysis dose and transferrin saturation increased significantly. However, in a multivariate linear regression model, changes in these factors did not significantly predict changes in ESA requirement. No relevant changes were noted in other erythropoiesis-modulating factors.

Conclusion

Frequent dose adjustments and the current ESA administration practice of withholding ESA doses does not seem to reduce ESA demand. On the contrary, such practice is likely to increase ESA requirement over time.

Schlagwörter

Stichwörter der Autor:innen

AnemiaChronic renal failureErythropoietin responsivenessErythropoietin-stimulating agentsHemodialysisRenal anemia

Autor:innen und Institutionen

  • Department of Molecular and Clinical Medicine-Nephrology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Zitieren

APA

Stefánsson, B. V., Haraldsson, B., & Nilsson, U. (2011). Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen. Nephron Extra. https://doi.org/10.1159/000329889

Vancouver

Stefánsson BV, Haraldsson B, Nilsson U. Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen. Nephron Extra. 2011. doi:10.1159/000329889

BibTeX
@article{Stefnsson2011,
  author = {Stefánsson, Bergur V and Haraldsson, Börje and Nilsson, Ulf},
  title = {Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen},
  journal = {Nephron Extra},
  year = {2011},
  doi = {10.1159/000329889}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche